Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President & CEO

EVP, Tech Ops and Admin

COO/CFO

EVP, Regulatory Affairs

Chief Medical Officer

Chief Scientific Officer

EVP & General Counsel

Chief Financial Officer

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therape...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	sold	Premium	Premium	Premium	President & CEO
2024-03-27	Premium	sold	Premium	Premium	Premium	EVP, Tech Ops and Admin
2024-03-27	Premium	sold	Premium	Premium	Premium	COO/CFO
2024-03-18	Premium	sold	Premium	Premium	Premium	EVP, Regulatory Affairs
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-11-15	Premium	bought	Premium	Premium	Premium	-
2023-11-13	Premium	bought	Premium	Premium	Premium	COO/CFO
2023-07-24	Premium	acquired	Premium	Premium	Premium	COO/CFO
2023-07-24	Premium	acquired	Premium	Premium	Premium	President & CEO
2023-07-24	Premium	acquired	Premium	Premium	Premium	EVP, Tech Ops and Admin
2023-06-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-04-04	Premium	bought	Premium	Premium	Premium	COO/CFO
2023-03-22	Premium	bought	Premium	Premium	Premium	President & CEO
2023-03-21	Premium	bought	Premium	Premium	Premium	President & CEO
2023-03-20	Premium	bought	Premium	Premium	Premium	EVP, Tech Ops and Admin
2023-03-20	Premium	bought	Premium	Premium	Premium	President & CEO
2023-03-20	Premium	bought	Premium	Premium	Premium	COO/CFO
2023-03-16	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-03-16	Premium	sold	Premium	Premium	Premium	EVP, Regulatory Affairs
2023-03-16	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2022-10-24	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2022-10-24	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2022-10-24	Premium	sold	Premium	Premium	Premium	EVP, Regulatory Affairs
2022-07-15	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer

GOSS - Gossamer Bio Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for GOSS